Press Releases
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI applies for listing on OTCQB in the United States
PHI is pursuing a dual listing on the US-based OTCQB Venture Market to provide US-based investors with the ability to invest in PHI. PHI aims to solidify further its presence in the major US market and within regenerative medicine, a rapidly evolving field, spearheaded by the United States globally. The application process has been initiated, and PHI expects to receive approval in the third quarter of 2024.
PHI bolsters Nordic sales presence with new distribution agreement between Altium and Kem-En-Tec Nordic
PHI is pleased to announce a new distribution agreement between its global distribution partner, Altium, and Kem-En-Tec Nordic, a lab supplier dedicated to supporting BioScience labs in Denmark, Sweden, Norway, Finland and Iceland.
PHI expands to Spanish and Portuguese markets through Altium’s new subcontract with Paralab
PHI is pleased to announce a strategic expansion into the Spanish and Portuguese markets, facilitated by a new subcontract between its global distribution partner, Altium, and Paralab.
PHI partners with University College London to use HoloMonitor in a first clinical research project
PHI is excited to announce a strategic partnership with University College London (UCL). Under this collaboration, PHI will lend a HoloMonitor® M4FL system for use in an ongoing research project at UCL, which runs alongside a clinical trial. This partnership represents PHI’s first direct step in a hospital setting to explore the clinical applications of its innovative technology.
PHI terminates agreement regarding liquidity provider
PHI today announces that the Company has terminated the liquidity provider agreement with Pareto Securities AB. The agreement will expire on July 31, 2024.
PHI secures a loan facility of in total SEK 7 million
PHI announces that the Company has secured a loan facility of in total SEK 7 million from Bizcap AB, and from that loan facility decided to draw a tranche of SEK 4.5 million.
PHI announces conference schedule for spring 2024
PHI is pleased to announce a strategic activity schedule for spring 2024, during which PHI will participate in select industry webinars and events.
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 14 March 2024
On Thursday, March 14, 2024, Phase Holographic Imaging PHI AB (publ), held an extraordinary general meeting. The following resolutions were passed at the meeting.
Shaping the future of Regenerative Medicine – PHI’s vision for QPI in Cell Therapy Manufacturing
PHI presents a comprehensive opinion piece detailing the versatility and potential the Company sees for Quantitative Phase Imaging (QPI) technology in Regenerative Medicine. PHI outlines how QPI will offer enhanced cell quality control in the cell manufacturing process, thereby addressing a central puzzle piece for making cell-based therapies safe, affordable, and accessible for all.
New Distributor Partner Manager at Altium set to enhance global sales for PHI
PHI is conveying the news that its global distributor, Altium ., has appointed a PHI-dedicated distributor partner manager. This strategic step is set to significantly enhance the reach and sales performance of PHI’s HoloMonitor technology on a global scale.